NO140821B - ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PYRIDO-PYRIMIDINE DERIVATIVES - Google Patents
ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PYRIDO-PYRIMIDINE DERIVATIVES Download PDFInfo
- Publication number
- NO140821B NO140821B NO741125A NO741125A NO140821B NO 140821 B NO140821 B NO 140821B NO 741125 A NO741125 A NO 741125A NO 741125 A NO741125 A NO 741125A NO 140821 B NO140821 B NO 140821B
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- pyrido
- acid
- oxo
- pyrimidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title claims description 4
- 150000008518 pyridopyrimidines Chemical class 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 1
- 230000026030 halogenation Effects 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 description 30
- 230000008018 melting Effects 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- -1 aryl benzene sulphonates Chemical class 0.000 description 20
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- QNQLQKRDBLQOEZ-UHFFFAOYSA-N 2-(6-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-3-yl)acetic acid Chemical compound C1=C(CC(O)=O)C(=O)N2C(C)CCCC2=N1 QNQLQKRDBLQOEZ-UHFFFAOYSA-N 0.000 description 2
- ANOUKFYBOAKOIR-UHFFFAOYSA-N 3,4-dimethoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1OC ANOUKFYBOAKOIR-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VFMCUTPRJLZEEW-UHFFFAOYSA-N 4h-pyrido[1,2-a]pyrimidine Chemical class C1=CC=CN2CC=CN=C21 VFMCUTPRJLZEEW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GVEKOTSOWVJLFX-UHFFFAOYSA-N ethyl 2-(6-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-3-yl)acetate Chemical compound C1CCC(C)N2C(=O)C(CC(=O)OCC)=CN=C21 GVEKOTSOWVJLFX-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940013688 formic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- QLAJNZSPVITUCQ-UHFFFAOYSA-N 1,3,2-dioxathietane 2,2-dioxide Chemical compound O=S1(=O)OCO1 QLAJNZSPVITUCQ-UHFFFAOYSA-N 0.000 description 1
- YHXUUIXBGUFOKL-UHFFFAOYSA-N 2-formylbutanedioic acid Chemical compound OC(=O)CC(C=O)C(O)=O YHXUUIXBGUFOKL-UHFFFAOYSA-N 0.000 description 1
- QUXLCYFNVNNRBE-UHFFFAOYSA-N 6-methylpyridin-2-amine Chemical compound CC1=CC=CC(N)=N1 QUXLCYFNVNNRBE-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- XKVFVISNJWSXMG-UHFFFAOYSA-N CCOC(=O)CCC1=CN=C2CCCC(N2C1=O)C Chemical compound CCOC(=O)CCC1=CN=C2CCCC(N2C1=O)C XKVFVISNJWSXMG-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- CHEXUHSFHDBGOK-UHFFFAOYSA-N diethyl 2-[amino-(3-methylpyridin-2-yl)methylidene]butanedioate Chemical compound C(C)OC(C(CC(=O)OCC)=C(N)C1=NC=CC=C1C)=O CHEXUHSFHDBGOK-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- GPICITVVVLYZNF-UHFFFAOYSA-N ethyl 2-(4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-3-yl)acetate Chemical compound C1CCCN2C(=O)C(CC(=O)OCC)=CN=C21 GPICITVVVLYZNF-UHFFFAOYSA-N 0.000 description 1
- FHSCYCCXMSMREH-UHFFFAOYSA-N ethyl 2-(6-methyl-4-oxopyrido[1,2-a]pyrimidin-3-yl)acetate Chemical compound C1=CC=C(C)N2C(=O)C(CC(=O)OCC)=CN=C21 FHSCYCCXMSMREH-UHFFFAOYSA-N 0.000 description 1
- YIXJMFGCUAPJCZ-UHFFFAOYSA-N ethyl 3-(4-oxopyrido[1,2-a]pyrimidin-3-yl)propanoate Chemical compound C1=CC=CN2C(=O)C(CCC(=O)OCC)=CN=C21 YIXJMFGCUAPJCZ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Foreliggende oppfinnelse angår en fremgangsmåte ved fremstilling av nye pyrido-[l,2-a]-pyrimidin-derivater. The present invention relates to a method for the production of new pyrido-[1,2-a]-pyrimidine derivatives.
De nye forbindelser som fremstilles ifølge foreliggende oppfinnelse, har formelen: The new compounds produced according to the present invention have the formula:
eller er salter og kvartære salter derav, or are salts and quaternary salts thereof,
hvor R^ er hydrogen eller C^-C^-alkyl, where R^ is hydrogen or C^-C^-alkyl,
I?2 er hydrogen eller C^-C^-alkyl; I 2 is hydrogen or C 1 -C 4 alkyl;
R er carboxy eller -C^-alkoxycarbonyl, carbamoyl, fenyl-laverealkylcarbamoyl eventuelt substituert med én eller to C^-C^-alkoxygrupper; eller en carboxylsyre-hydrazidogruppe; og n er 1 eller 2. R is carboxy or -C 1 -C 4 -Alkoxycarbonyl, carbamoyl, phenyl-lower alkylcarbamoyl optionally substituted with one or two C 1 -C 4 -Alkoxy groups; or a carboxylic acid hydrazido group; and n is 1 or 2.
Saltene av forbindelsene med formel I kan dannes med uorgan- The salts of the compounds of formula I can be formed with inorganic
iske eller organiske syrer, som saltsyre, hydrogenbromid, fosfor- ic or organic acids, such as hydrochloric acid, hydrogen bromide, phosphoric
syre, svovelsyre, perklorsyre, maursyre, eddiksyre, citronsyre, malinsyre, glutamsyre, amygdalinsyre, salicylsyre, etc. acid, sulfuric acid, perchloric acid, formic acid, acetic acid, citric acid, malic acid, glutamic acid, amygdalic acid, salicylic acid, etc.
De kvartære salter av forbindelsene med formel I dannes med konvensjonelle kvaterneringsmidler, f.eks. alkylhalogenider (f.eks. methyljodid, ethyljodid, etc), dialkylsulfater (f.eks. dimethyl- The quaternary salts of the compounds of formula I are formed with conventional quaternizing agents, e.g. alkyl halides (e.g. methyl iodide, ethyl iodide, etc), dialkyl sulfates (e.g. dimethyl-
sulfat) eller alkyl- eller aryl-benzensulfonater eller p-toluensulfonater. sulphate) or alkyl or aryl benzene sulphonates or p-toluene sulphonates.
Forbindelsene med formel i og salter og kvartære salter The compounds of formula I and salts and quaternary salts
derav, fremstilles ifølge oppfinnelsen ved å redusere en forbind- thereof, is produced according to the invention by reducing a compound
else med formelen: else with the formula:
hvor , R2, Rg og n er som ovenfor angitt, til en forbindelse med formelen: where , R2, Rg and n are as indicated above, to a compound with the formula:
hvor R^-gruppen eventuelt kan overføres til andre betydninger av R^-gruppen, hvorefter eventuelt en således erholdt forbindelse med formel I overføres til dens syreaddisjonssalt eller kvartære salt, eller en forbindelse med formel I frigjøres fra dens syreaddisjonssalt eller kvartære salt. where the R^ group can optionally be transferred to other meanings of the R^ group, after which a thus obtained compound of formula I is transferred to its acid addition salt or quaternary salt, or a compound of formula I is released from its acid addition salt or quaternary salt.
Reduksjonen kan fortrinnsvis utføres ved katalytisk hydrogen-ering. Hydrogeneringen kan utføres ved en temperatur mellom 0° og 10O°C og under atmosfæ ret rykk eller under et trykk på på 1 - 50 atm. The reduction can preferably be carried out by catalytic hydrogenation. The hydrogenation can be carried out at a temperature between 0° and 100°C and under atmospheric pressure or under a pressure of 1 - 50 atm.
Reaksjonen utføres i et oppløsningsmiddel.. Som reaksjons - medium kan vann, alkanoler (f.eks. methanol eller ethanol), estere (f.eks. ethylacetat) , ketoner (f.eks. aceton eller methylethyl-keton) eller organiske syrer (f.eks. eddiksyre), eller blandinger derav, anvendes. The reaction is carried out in a solvent. The reaction medium can be water, alkanols (e.g. methanol or ethanol), esters (e.g. ethyl acetate), ketones (e.g. acetone or methylethyl ketone) or organic acids ( e.g. acetic acid), or mixtures thereof, are used.
Som katalysator kan konvensjonelle hydrogeneringskatalysatorer anvendes. Det foretrekkes å anvende en palladium-på-trekullkatalysator, Raney-nikkel, platina eller platinaoxyd. As a catalyst, conventional hydrogenation catalysts can be used. It is preferred to use a palladium-on-charcoal catalyst, Raney nickel, platinum or platinum oxide.
Under hydrogeneringen blir pyridinringen i utgangsmaterialet med formel II mettet og tar opp 2 mol hydrogen. Efter absorpsjonen av den beregnede mengde hydrogen, fjernes katalysatoren (fortrinnsvis ved filtrering, sent rifugering, sedimentering eller dekanter-ing), og oppløsningsmidlet avdestilleres. Den således erholdte forbindelse med formel III eller dens syreaddisjonssalt kan omkrystalliseres fra et passende oppløsningsmiddel om nødvendig. During the hydrogenation, the pyridine ring in the starting material with formula II becomes saturated and takes up 2 moles of hydrogen. After the absorption of the calculated amount of hydrogen, the catalyst is removed (preferably by filtration, late rifugation, sedimentation or decantation), and the solvent is distilled off. The thus obtained compound of formula III or its acid addition salt can be recrystallized from a suitable solvent if necessary.
I forbindelsen med formel III kan, om ønskes, en R^-gruppe overføres til andre betydninger av R^-gruppen ved i og for seg kjente metoder. En alkoxycarbonylgruppe kan således overføres til carboxylgruppen ved hydrolyse. Reaksjonen kan fortrinnsvis utføres under alkaliske betingelser, ved å anvende et alkali-hydroxyd, fortrinnsvis en vandig natrium- eller kalium-hydroxydoppløsning. En alkoxycarbonylgruppe kan over- In the connection with formula III, if desired, an R^ group can be transferred to other meanings of the R^ group by methods known per se. An alkoxycarbonyl group can thus be transferred to the carboxyl group by hydrolysis. The reaction can preferably be carried out under alkaline conditions, by using an alkali hydroxide, preferably an aqueous sodium or potassium hydroxide solution. An alkoxycarbonyl group can over-
føres til en syrehydrazidgruppe ved behandling med hydrazin; is converted to an acid hydrazide group by treatment with hydrazine;
idet det sistnevnte fortrinnsvis kan anvendes i form av en alko-holisk hydrazinoppløsning; eller salter og hydratet av hydrazin kan anvendes. Carboxylgruppen kan overføres til en alkoxycarbonylgruppe (f.eks. ethoxycarbonyl) ved behandling med en alkohol (f.eks. ethanol) i nærvær av et oppløsningsmiddel (f.eks. benzen). Carboxylgruppen kan overføres til et syreamid ved omsetning med det tilsvarende amin, eventuelt i nærvær av et oppløsningsmiddel (f.eks. xylen). Den frie carboxylsyre kan overføres til syreklorider ved behandling med et halogeneringsmiddel (f.eks. thionylklorid, fosforoxyklorid, etc). Syrehalogenidene kan overføres til de frie syrer ved behandling med vann, eller til alkoxycarbonylestere ved behandling med den tilsvarende alkohol, eller syreamider ved behandling med det tilsvarende amin. since the latter can preferably be used in the form of an alcoholic hydrazine solution; or salts and the hydrate of hydrazine may be used. The carboxyl group can be transferred to an alkoxycarbonyl group (eg, ethoxycarbonyl) by treatment with an alcohol (eg, ethanol) in the presence of a solvent (eg, benzene). The carboxyl group can be transferred to an acid amide by reaction with the corresponding amine, possibly in the presence of a solvent (e.g. xylene). The free carboxylic acid can be transferred to acid chlorides by treatment with a halogenating agent (e.g. thionyl chloride, phosphorus oxychloride, etc.). The acid halides can be transferred to the free acids by treatment with water, or to alkoxycarbonyl esters by treatment with the corresponding alcohol, or acid amides by treatment with the corresponding amine.
Forbindelsene med formel I kan overføres til deres syreaddi-sjonssalter og kvartære salter ved i og for seg kjente metoder. Man kan gå frem ved å omsette basen med formel I med en passende ekvi-molar mengde av den tilsvarende syre eller kvaterneringsmiddel i nærvær av et organisk oppløsningsmiddel. Som syre er både organiske og uorganiske syrer egnet, f.eks. saltsyre, hydrogenbromid, fosfor-syre, svovelsyre, perklorsyre, maursyre, eddiksyre, citronsyre, amygdalinsyre, malinsyre, glutamsyre, salicylsyre, etc. Som kvaterneringsmiddel kan anvendes f.eks. alkylhalogenider (som methyljodid, ethyljodid), dialkylsulfater (f .eks. dimethylsulfat), alkyl- og aryl-benzensulfonater og p-toluensulfonater. The compounds of formula I can be converted to their acid addition salts and quaternary salts by methods known per se. One can proceed by reacting the base of formula I with a suitable equimolar amount of the corresponding acid or quaternizing agent in the presence of an organic solvent. Both organic and inorganic acids are suitable as acid, e.g. hydrochloric acid, hydrogen bromide, phosphoric acid, sulfuric acid, perchloric acid, formic acid, acetic acid, citric acid, amygdalic acid, malic acid, glutamic acid, salicylic acid, etc. As a quaternizing agent, e.g. alkyl halides (such as methyl iodide, ethyl iodide), dialkyl sulphates (e.g. dimethyl sulphate), alkyl and aryl benzene sulphonates and p-toluene sulphonates.
Utgangsmaterialene med formel II kan fremstilles ved å ring-slutte en forbindelse med formelen: The starting materials of formula II can be prepared by ring-closing a compound of the formula:
hvor R^ , R^ p R^°9 n er som ovenfor angitt, og Rg er alkoxycarbonyl. Ringslutningen kan utføres i nærvær av et inert oppløsningsmiddel eller et surt kondenseringsmiddel, f.eks. fosforoxyklorid, fosfor-trihalogenider, polyfosforsyre, etc, ved en temperatur mellom 25° og 4oO o C'. Fremstillingen av utgangsmaterialet er beskrevet i DOS 2.315.422. where R^ , R^ p R^°9 n are as indicated above, and Rg is alkoxycarbonyl. The cyclization can be carried out in the presence of an inert solvent or an acidic condensing agent, e.g. phosphorus oxychloride, phosphorus trihalides, polyphosphoric acid, etc., at a temperature between 25° and 4oO o C'. The production of the starting material is described in DOS 2,315,422.
Forbindelsene med formel I har nyttige terapeutiske egen-skaper og oppviser analgetisk, antiinflammatorisk og antipyretisk virkning, og utøver andre ønskede virkninger på sentralnervesys-temet (f.eks. narkotisk og psykosedativ virkning, etc). The compounds of formula I have useful therapeutic properties and exhibit analgesic, anti-inflammatory and antipyretic effects, and exert other desired effects on the central nervous system (e.g. narcotic and psychosedative effects, etc.).
Fremgangsmåteforbindelsene kan anvendes til å fremstille farmasøytiske preparater omfattende som aktiv bestanddel en forbindelse med formel I eller et syreaddisjonssalt eller kvartært salt derav i blanding med passende inerte faste eller flytende bærere eller fortynningsmidler. The process compounds can be used to prepare pharmaceutical preparations comprising as active ingredient a compound of formula I or an acid addition salt or quaternary salt thereof in mixture with suitable inert solid or liquid carriers or diluents.
Eksempel 1 Example 1
4>4 g (0,02 mol) 3_(carboxymethyl) -6-methyl^-oxo^H-pyrido-l^l ,2-a]-pyrimidin ble suspendert i 60 ml iseddik og hydro-genert under atmosfæretrykk i nærvær av 1,5 g trekull. 4>4 g (0.02 mol) 3-(carboxymethyl)-6-methyl^-oxo^H-pyrido-1^1,2-a]-pyrimidine was suspended in 60 ml of glacial acetic acid and hydrogenated under atmospheric pressure in the presence of 1.5 g of charcoal.
Den beregnede mengde hydrogen ble absorbert i løpet av 30 minutter, hvorefter katalysatoren ble frafiltrert og oppløsningen inndampet til tørrhet i vakuum. De 8>2 g gjenværende olje ble om-kryst allisert fra 9 ml 96%-ig alkohol. Man fikk 3,3 g (75%) av det hvitf arvede 3-(carboxymethyl)-6-methyl-4-oxo-6,7,8 >9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin med smeltepunkt 193 - 194°C. Smeltepunktet forble uforandret ved omkrystallisasjon. The calculated amount of hydrogen was absorbed within 30 minutes, after which the catalyst was filtered off and the solution evaporated to dryness in vacuo. The 8>2 g of remaining oil was recrystallized from 9 ml of 96% alcohol. 3.3 g (75%) of the white colored 3-(carboxymethyl)-6-methyl-4-oxo-6,7,8>9-tetrahydro-4H-pyrido-[1,2-a]- pyrimidine with melting point 193 - 194°C. The melting point remained unchanged upon recrystallization.
Analyse: Analysis:
Eksempel 2 Example 2
6,0 g (0,15 mol) natriumhydroxyd ble oppløst i 60 ml vann. 6.0 g (0.15 mol) of sodium hydroxide was dissolved in 60 ml of water.
Til den således erholdte oppløsning ble 14,4 9 (0,05 mol) 3-(ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tet rahydro-4H-pyrido-[1,2-a ] - pyrimidin-hydroklorid tilsatt, og oppløsningen ble omrørt ved værelsetemperatur i 3 timer, hvorefter pH-verdien ble innstilt med saltsyre 1:1 (ca. 8 ml) på- 7> og oppløsningen ble avfarvet med trekull. pH-verdien av den avfarvede oppløsning ble innstilt på 4 (ved en lavere pH-verdi oppløses syren). Oppløsningen ble hensatt i noen timer i et kjøleskap, og de utfelte krystaller ble frafiltrert. Man fikk 3,6 g (32%) 3-(carboxymethyl)-6-methyl-4-oxo-6,7,8,9-tet ra - hydro-4H-pyrido-[1,2-a]-pyrimidin med smeltepunkt 191°C Den vandige morlut ble inndampet og residuet på 10 g ble oppløst i 20 ml vann ved oppvarmning. Ved avkjøling fikk man 3,5 g (30%) av syren, med smeltepunkt 192°C. Totalutbyttet var 7,1 g (62%). Smeltepunktet stiger til 193 - 194°C ved omkrystallisasjon fra 96%-ig alkohol. To the solution thus obtained was added 14.4 9 (0.05 mol) 3-(ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1, 2-a ] - pyrimidine hydrochloride added, and the solution was stirred at room temperature for 3 hours, after which the pH value was adjusted with hydrochloric acid 1:1 (approx. 8 ml) and the solution was decolorized with charcoal. The pH value of the decolorized solution was set to 4 (at a lower pH value the acid dissolves). The solution was left for a few hours in a refrigerator, and the precipitated crystals were filtered off. 3.6 g (32%) of 3-(carboxymethyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine were obtained with melting point 191°C The aqueous mother liquor was evaporated and the residue of 10 g was dissolved in 20 ml of water by heating. On cooling, 3.5 g (30%) of the acid was obtained, with a melting point of 192°C. The total yield was 7.1 g (62%). The melting point rises to 193 - 194°C on recrystallization from 96% alcohol.
De således erholdte krystaller gir ikke noen smeltepunktsdepresjon med produktet erholdt ifølge eksempel 1. The crystals thus obtained do not cause any melting point depression with the product obtained according to example 1.
Når der i ovenstående fremgangsmåte anvendes 3~(ethoxycarbonyl-methyl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin som ut - gangsmateriale, fåes 3-(carboxymethyl)-4-oxo-6,7 > 8 > 9-t et rahydro-4H-pyrido-[1,2-a]-pyrimidin med smeltepunkt 174 - 175°C i et utbytte på 80%. When in the above method 3~(ethoxycarbonyl-methyl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine is used as starting material, 3-( carboxymethyl)-4-oxo-6,7 > 8 > 9-t a rahydro-4H-pyrido-[1,2-a]-pyrimidine with melting point 174 - 175°C in a yield of 80%.
Eksempel 3 Example 3
53,7 g (0,2 mol) 3-(ethoxycarbonyl-methyl)-4-oxo-4H-pyrido-[1,2-a]-pyrimidin-hydroklorid ble oppløst i 250 ml vann. Efter tilsetning av IO ml saltsyre og 20 g palladium-trekullkatalysator ble hydrogeneringen utført ved et trykk på 5 - 10 atm. Den beregnede mengde hydrogen ble absorbert, katalysatoren ble frafiltrert og pH 53.7 g (0.2 mol) of 3-(ethoxycarbonyl-methyl)-4-oxo-4H-pyrido-[1,2-a]-pyrimidine hydrochloride was dissolved in 250 ml of water. After adding 10 ml of hydrochloric acid and 20 g of palladium-charcoal catalyst, the hydrogenation was carried out at a pressure of 5 - 10 atm. The calculated amount of hydrogen was absorbed, the catalyst was filtered off and the pH
innstilt på 7 ved tilsetning av en 20%-ig natriumcarbonatoppløs-ning. Den erholdte oppløsning ble avfarvet med trekull og filtrert. Den klare oppløsning ble ekstrahert tre ganger med 300 ml benzen. set to 7 by adding a 20% sodium carbonate solution. The resulting solution was decolorized with charcoal and filtered. The clear solution was extracted three times with 300 ml of benzene.
De forenede ekstrakter ble tørret over natriumsulfat, oppløsningen ble filtrert og filtratet inndampet til tørrhet. 32,0 g (68%) av et krystallinsk produkt ble erholdt, som smeltet ved 63 - 66°C. Ekstrahering av den vandige morlut med kloroform og opparbeidelse The combined extracts were dried over sodium sulfate, the solution was filtered and the filtrate was evaporated to dryness. 32.0 g (68%) of a crystalline product was obtained, which melted at 63-66°C. Extraction of the aqueous mother liquor with chloroform and work-up
av det erholdte ekstrakt, ga ytterligere 2,8 9 ( 5, 5fø) av det erholdte produkt, tilsammen et utbytte på 73,5%. Omkrystallisasjon av produktet fra en blanding av alkohol-petrolether ga snehvit 3- of the extract obtained, gave a further 2.89 (5.5fø) of the product obtained, a total yield of 73.5%. Recrystallization of the product from an alcohol-petroleum ether mixture gave snow white 3-
(ethoxyca rbonyImethyl)-4~oxo-6,7,8,9-t etrahydro-4H-pyrido-[1,2-a]-pyrimidin med smeltepunkt 65 - 66°C. (ethoxyca rbonyImethyl)-4~oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine with melting point 65 - 66°C.
Analyse: Analysis:
Når 3-(ethoxycarbony1-methyl)-7-methyl-4-oxo-4H-pyrido-[1,2-a]-pyrimidin-hydroklorid anvendes som utgangsmateriale, fåes 3-(ethoxycarbony1-methyl)-7-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin i form av en ukrystalliserbar olje. Smeltepunktet for hydrokloridet er 146 - l47°C. When 3-(ethoxycarbonyl1-methyl)-7-methyl-4-oxo-4H-pyrido-[1,2-a]-pyrimidine hydrochloride is used as starting material, 3-(ethoxycarbonyl1-methyl)-7-methyl-4 -oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine in the form of a non-crystallizable oil. The melting point of the hydrochloride is 146 - 147°C.
Når 3-(ethoxycarbonylmethyl)-8-methyl-4-oxo-4H-pyrido-[1,2-a]-pyrimidin-hydroklorid anvendes som utgangsmateriale, fåes 3-(ethoxycarbonyl-methyl)-8-methyl-4-oxo-4H-pyrido-[l,2-a]-pyrimidin med smeltepunkt 44 - 45°C. When 3-(ethoxycarbonylmethyl)-8-methyl-4-oxo-4H-pyrido-[1,2-a]-pyrimidine hydrochloride is used as starting material, 3-(ethoxycarbonyl-methyl)-8-methyl-4-oxo is obtained -4H-pyrido-[1,2-a]-pyrimidine with melting point 44 - 45°C.
Eksempel 4 Example 4
0,25 g (1 mmol) 3-(ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[l,2-a]-pyrimidin ble oppløst i 1 ml absolutt alkohol og 0,1 ml (2 mmol) 100%-ig hydrazinhydrat ble tilsatt. Efter 1 dags henstand ved værelsetemperatur ble oppløsningen inndampet til tørrhet, og det gjenværende, langsomt krystalliserende produkt ble omkrystallisert fra en alkohol-etherblanding. Man fikk 0,17 g (72%) hvitfarvet 6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin-3-(methyl-carbohydrazid) med smeltepunkt 132 - 133°C. 0.25 g (1 mmol) of 3-(ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine was dissolved in 1 ml of absolute alcohol and 0.1 ml (2 mmol) of 100% hydrazine hydrate were added. After standing for 1 day at room temperature, the solution was evaporated to dryness, and the remaining, slowly crystallizing product was recrystallized from an alcohol-ether mixture. 0.17 g (72%) of white colored 6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine-3-(methyl-carbohydrazide) was obtained with melting point 132 - 133°C.
Smeltepunktet forandres ikke ved omkrystallisasjon. The melting point is not changed by recrystallization.
Analyse: Analysis:
Eksempel 5 Example 5
25,0 g (0,1 mol) 3—(ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[l,2-a]-pyrimidin ble oppløst i 50 ml absolutt aceton og 13,2 g (0,105 mol) friskt destillert dimethylsulfat ble tilsatt til oppløsningen. Oppløsningen ble holdt i IO minutter ved 4o°C og så hensatt ved værelsetemperatur. Den neste dag ble de utfelte krystaller frafiltrert og vasket med en liten mengde absolutt aceton. Det erholdte produkt ble omkrystallisert fra en dobbel mengde absolutt alkohol. Man fikk således 21 g 25.0 g (0.1 mol) of 3-(ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine was dissolved in 50 ml of absolute acetone and 13.2 g (0.105 mol) of freshly distilled dimethyl sulfate was added to the solution. The solution was kept for 10 minutes at 4o°C and then left at room temperature. The next day, the precipitated crystals were filtered off and washed with a small amount of absolute acetone. The product obtained was recrystallized from a double amount of absolute alcohol. Thus, 21 g were obtained
(56%) hvitfarvet 3~(ethoxycarbonyl-methyl)-1,6-dimethyl-4-oxo-6,7,8 ,9-t et rahydro -4H-pyrido-[1,2-a ] -pyrimidinium-met ho sulfat med smeltepunkt 150°C. Smeltepunktet forandres ikke ved omkrystallisasjon. (56%) off-white 3~(ethoxycarbonyl-methyl)-1,6-dimethyl-4-oxo-6,7,8,9-t rahydro -4H-pyrido-[1,2-a]-pyrimidinium-met ho sulfate with melting point 150°C. The melting point is not changed by recrystallization.
Analyse: Analysis:
Når der i ovenstående fremgangsmåte anvendes 3-(ethoxycarbonyl -methyl)-4-oxo-6,7,8,9-tet rahydro~4H-pyrido-[1,2-a]-pyrimidin som utgangsmateriale , fåes 3-(ethoxycarbonyl-methyl)-l-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidinium-methosulfat med smeltepunkt l4l - l42°C When in the above method 3-(ethoxycarbonyl-methyl)-4-oxo-6,7,8,9-tetrahydro~4H-pyrido-[1,2-a]-pyrimidine is used as starting material, 3-(ethoxycarbonyl -methyl)-1-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidinium methosulphate with melting point 141 - 142°C
Eksempel 6 Example 6
I et apparat forsynt med en vannfraskillingskolonne ble 22,2 g (0,1 mol) 3-(carboxymethyl)-6-methyl-4-oxo-6,7,8,9-tet rahydro-4H-pyrido-[ 1,2-a ].-pyrimidin , 12,1 g (0,1 mol) 2-f enyl-ethylamin og 100 ml xylen kokt under tilbakeløp i 3 timer, mens 1,8 ml vann ble oppsamlet i kjøleren. Oppløsningen ble så inndampet til tørrhet. Man fikk 32,3 g (99%) 3"(N-2-fenyl-ethyl)-carboxamido-methyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin i form av en ikke krystalliserende olje. Ved oppløsning av 3,35 g (3,01 mol) av oljen i 3 ml alkohol og tilsetning av 1,5 ml 70%-ig perklorsyre, fikk man 3,0 g (71%) av det blekgule 3-(N-2-f enyl - methyl)-carboxamido-methyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidinium-perklorat med smeltepunkt 174 - 176°C. Smeltepunktet stiger efter omkrystallisasjon fra en 8 ganger så stor mengde ethanol til 176 - 177°C. In an apparatus equipped with a water separation column, 22.2 g (0.1 mol) of 3-(carboxymethyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[ 1, 2-α].-pyrimidine, 12.1 g (0.1 mol) of 2-phenylethylamine and 100 ml of xylene were refluxed for 3 hours, while 1.8 ml of water was collected in the condenser. The solution was then evaporated to dryness. 32.3 g (99%) of 3"(N-2-phenyl-ethyl)-carboxamido-methyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1 ,2-a]-pyrimidine in the form of a non-crystallizing oil. By dissolving 3.35 g (3.01 mol) of the oil in 3 ml of alcohol and adding 1.5 ml of 70% perchloric acid, 3 was obtained .0 g (71%) of the pale yellow 3-(N-2-phenyl-methyl)-carboxamido-methyl-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[ 1,2-a]-pyrimidinium perchlorate with a melting point of 174 - 176° C. The melting point rises after recrystallization from an 8 times greater amount of ethanol to 176 - 177° C.
Analyse: Analysis:
Ved ovenstående fremgangsmåte å anvende 2-(3,4-dimethoxy-fenyl)-ethylamin som aminkomponent, fåes 3~[N-2-(3,4-dimethoxy-fenyl)-ethyl]-carboxamido-methy1-6-methyl-4-oxo-6,7,8,9-tet rahydro-4H-pyrido-[1,2-a]-pyrimidin i et utbytte på 99% i form av en ikke krystalliserende olje. By the above procedure using 2-(3,4-dimethoxy-phenyl)-ethylamine as the amine component, 3~[N-2-(3,4-dimethoxy-phenyl)-ethyl]-carboxamido-methyl-6-methyl- 4-oxo-6,7,8,9-tet rahydro-4H-pyrido-[1,2-a]-pyrimidine in a yield of 99% in the form of a non-crystallizing oil.
Eksempel 7 Example 7
2,6 g (0,01 mol) 3-(ethoxycarbonyl-methyl)-6,8-dimethyl-4-oxo-4H-pyrido-[1,2-a]-pyrimidin oppløses i 30 ml ethanol og hydrogeneres under atmosfæretrykk i nærvær av 1,0 g nøytral, 10% palladiumholdig palladium-trekullkatalysator. Efter adsorpsjon av den beregnede hydrogenmengde slutter reaksjonen, hvorefter katalysatoren frafiltreres og den alkoholiske oppløsning inndampes. På denne måte fåes 2,2 g (84,5%) 3-(ethoxycarbonyl-methyl)-6,8-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[l,2-a]-pyrimidin som en farveløs olje. 2.6 g (0.01 mol) of 3-(ethoxycarbonyl-methyl)-6,8-dimethyl-4-oxo-4H-pyrido-[1,2-a]-pyrimidine are dissolved in 30 ml of ethanol and hydrogenated under atmospheric pressure in the presence of 1.0 g of neutral, 10% palladium-containing palladium-charcoal catalyst. After adsorption of the calculated amount of hydrogen, the reaction ends, after which the catalyst is filtered off and the alcoholic solution is evaporated. In this way, 2.2 g (84.5%) of 3-(ethoxycarbonyl-methyl)-6,8-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2 -α]-pyrimidine as a colorless oil.
Analyse: Analysis:
0,5 g (0,0019 mol) av ovenstående ester oppvarmes til kok-ning med 5 ml 5%-ig saltsyre i 0,5 timer, og derefter inndampes oppløsningen i vakuum. Det krystallinske residuum tørres i eksikator over fosforpentoxyd til konstant vekt. Man får 4,3 g (-95,5%) hvitt krystallinsk 3-(carboxymethyl) -6,8-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[l,2-a]-pyrimidin med smeltepunkt 120°C og decarboxylering ved l44°C. 0.5 g (0.0019 mol) of the above ester is heated to boiling with 5 ml of 5% hydrochloric acid for 0.5 hours, and then the solution is evaporated in vacuo. The crystalline residue is dried in a desiccator over phosphorus pentoxide to constant weight. 4.3 g (-95.5%) of white crystalline 3-(carboxymethyl)-6,8-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2- α]-pyrimidine with melting point 120°C and decarboxylation at 144°C.
Analyse: Analysis:
Eksempel 8 Example 8
2,46 g (0,01 mol) 3-(2-ethoxycarbonyl-ethyl)-4-oxo-4H-pyrido-[1,2-a]-pyrimidin oppløses i lOO ml ethanol og hydrogeneres i nærvær av 1,0 g 10%-ig palladium-trekullkatalysator. Efter at den beregnede mengde hydrogen er adsorbert, frafiltreres katalysatoren, og den alkoholiske oppløsning inndampes. Man får 2,0 g (80%) av hvitt, krystallinsk 3-(2-ethoxycarbonyl-ethyl)-4-oxo-6,7,8,9~tetrahydro-4H-pyrido-[l,2-a]-pyrimidin med smeltepunkt 48 - 50°C. 2.46 g (0.01 mol) of 3-(2-ethoxycarbonyl-ethyl)-4-oxo-4H-pyrido-[1,2-a]-pyrimidine are dissolved in 100 ml of ethanol and hydrogenated in the presence of 1.0 g 10% palladium-charcoal catalyst. After the calculated amount of hydrogen has been adsorbed, the catalyst is filtered off and the alcoholic solution is evaporated. 2.0 g (80%) of white, crystalline 3-(2-ethoxycarbonyl-ethyl)-4-oxo-6,7,8,9~tetrahydro-4H-pyrido-[1,2-a]- pyrimidine with melting point 48 - 50°C.
Analyse: Analysis:
Når 3- (2 -ethoxyca rbonyl -ethyl) -6-methyl-4-oxo -ifH-pyrido-[1,2-a]-pyrimidin anvendes som utgangsmateriale, fåes 3-(2-ethoxycarbonyl-ethyl)-6-methyl-4-oxo-6,7,8,9-tet rahydro-4H-pyrido-[l,2-a]-pyrimidin i form av en ukrystalliserbar farveløs olje. Utbytte: 8.5%. Smeltepunkt av hydrokloridet 130 - 132°C. Analyse: When 3-(2-ethoxycarbonyl-ethyl)-6-methyl-4-oxo-ifH-pyrido-[1,2-a]-pyrimidine is used as starting material, 3-(2-ethoxycarbonyl-ethyl)-6- methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine in the form of a non-crystallizable colorless oil. Dividend: 8.5%. Melting point of the hydrochloride 130 - 132°C. Analysis:
Eksempel 9 Example 9
4,45 g (0,02 mol) 3-(carboxy-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin suspenderes i 6o ml methanol og mettes med vannfritt gassformig hydrogenklorid ved 5 - 10°C. Reaksjonsblandingen hensettes over natten, og den lysegule oppløsning inndampes og residuet oppløses i 30 ml vann, hvorefter pH innstilles på 7 ved tilsetning av mettet natrium-carbonatoppløsning. Oppløsningen avfarves med trekull som frafiltreres. Den klare oppløsning ekstraheres med 3 x 40 ml benzen. De forenede benzenekstrakter tørres over natriumsulfat, oppløs-ningen frafiltreres og inndampes. Man får 3,0 g (63,5%) av en lysegul olje som oppløses i 2 ml ethanol, og 2 ml ethanol inneholdende 25% hydrogenklorid tilsettes til oppløsningen. Det utfelte hvite 6-methyl-3-(methoxycarbonyl-methyl)-4-oxo-6,7,8,9-tet rahydro-4H-pyrido-[1,2-a]-pyrimidin f raf ilt reres. Smeltepunkt: 222°C. 4.45 g (0.02 mol) of 3-(carboxy-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine are suspended in 60 ml of methanol and saturated with anhydrous gaseous hydrogen chloride at 5 - 10°C. The reaction mixture is allowed to stand overnight, and the pale yellow solution is evaporated and the residue is dissolved in 30 ml of water, after which the pH is adjusted to 7 by adding a saturated sodium carbonate solution. The solution is de-coloured with charcoal which is filtered off. The clear solution is extracted with 3 x 40 ml of benzene. The combined benzene extracts are dried over sodium sulphate, the solution is filtered off and evaporated. 3.0 g (63.5%) of a light yellow oil is obtained which is dissolved in 2 ml of ethanol, and 2 ml of ethanol containing 25% hydrogen chloride is added to the solution. The precipitated white 6-methyl-3-(methoxycarbonyl-methyl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine is filtered off. Melting point: 222°C.
Analyse: Analysis:
Eksempel IO Example IO
3,54g (0,015 mol) 3-(ethoxycarbonyl-methyl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidin oppløses i 5 ml aceton, og '3,0 ml methyljodid tilsettes til oppløsningen. Oppløsningen om-røres og hensettes i 5 dager i et mørkt rom. Det utfelte krystallinske produkt frafiltreres og vaskes med aceton. 4,9 g (86,5%) lysegule krystaller fåes, som smelter ved 150 - 153°C. Efter omkrystallisasjon fra ethanol er smeltepunktet av 3-(ethoxycarbonyl- 3.54 g (0.015 mol) of 3-(ethoxycarbonyl-methyl)-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine is dissolved in 5 ml of acetone, and 3.0 ml of methyl iodide is added to the solution. The solution is stirred and left for 5 days in a dark room. The precipitated crystalline product is filtered off and washed with acetone. 4.9 g (86.5%) of light yellow crystals are obtained, which melt at 150 - 153°C. After recrystallization from ethanol, the melting point of 3-(ethoxycarbonyl-
methyl )-l-methyl-4-oxo-6, 7,8, 9-t et rahydro-4H-pyrido-[l ,2-a]-pyrimidin-jodidet 154 - 155°C. methyl )-1-methyl-4-oxo-6,7,8,9-t rahydro-4H-pyrido-[1,2-a]-pyrimidine iodide 154-155°C.
Analyse: Analysis:
Eksempel 11 Example 11
2,18 g (0,01 mol) 4-oxo-4H-pyrido-[l,2-a]-pyrimidin-3-(methyl-carbohydrazid) (smp. 228 - 229°C) oppløses i 700 ml ethanol under oppvarmning, hvorefter 10,0 g av en Raney-nikkelkatalysator tilsettes, og reaksjonsblandingen kokes under tilbake - løp inntil utviklingen av ammoniakkgass opphører (3 - 3,5 timer). Katalysatoren frafiltreres, og filtratet inndampes. Hvitt, krystallinsk 3-(carbamoyl-methyl)-4-oxo-6,7,8 >9-tetrahydro-4h-pyrido-[l,2-a]-pyrimidin fåes. Smeltepunkt: 182 - 183°C efter omkrystallisasjon fra ethanol. Utbytte: 95%. 2.18 g (0.01 mol) of 4-oxo-4H-pyrido-[1,2-a]-pyrimidine-3-(methyl-carbohydrazide) (m.p. 228 - 229°C) are dissolved in 700 ml of ethanol under heating, after which 10.0 g of a Raney nickel catalyst is added, and the reaction mixture is refluxed until the evolution of ammonia gas ceases (3 - 3.5 hours). The catalyst is filtered off, and the filtrate is evaporated. White, crystalline 3-(carbamoyl-methyl)-4-oxo-6,7,8>9-tetrahydro-4h-pyrido-[1,2-a]-pyrimidine is obtained. Melting point: 182 - 183°C after recrystallization from ethanol. Yield: 95%.
Analyse: Analysis:
Eksempel 12 Example 12
1,6 g (6,5 mmol) 6-methyl-4-oxo-6,7,8>9-tetrahydro-4H-pyrido-[l,2-a]-pyrimidin-3-(methyl-carbohydrazid) oppløses i 50 ml ethanol i nærvær av 10 g Raney-nikkelkatalysator. Reaksjonsblandingen kokes, under tilbakeløp i 2 timer, hvorefter katalysatoren frafiltreres, og det alkoholiske filtrat inndampes. Man får 1,4 g lysegul olje som behandles med 10 ml ethanol inneholdende 20% hydrogenklorid. De utfelte krystaller frafiltreres og tørres. Man får 1,15 g (68%) 3-(carbamoyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[l,2-a]-pyrimidin-hydroklorid med smeltepunkt 235 - 236°C. Smeltepunktet forblir uforandret efter omkrystallisasjon fra ethanol inneholdende hydrogenklorid. Analyse: 1.6 g (6.5 mmol) of 6-methyl-4-oxo-6,7,8>9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine-3-(methyl-carbohydrazide) is dissolved in 50 ml of ethanol in the presence of 10 g of Raney nickel catalyst. The reaction mixture is boiled under reflux for 2 hours, after which the catalyst is filtered off and the alcoholic filtrate is evaporated. 1.4 g of light yellow oil is obtained which is treated with 10 ml of ethanol containing 20% hydrogen chloride. The precipitated crystals are filtered off and dried. 1.15 g (68%) of 3-(carbamoyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido-[1,2-a]-pyrimidine- hydrochloride with melting point 235 - 236°C. The melting point remains unchanged after recrystallization from ethanol containing hydrogen chloride. Analysis:
Eksempel 13 Example 13
Fremstilling av utgangsmaterialer: Preparation of starting materials:
A) 14,6 g (0,05 mol) 2-[(5-methyl-2-pyridyl)-amino-methylen]-ravsyre-diethylester oppløses i 100 ml difylolje ved 130°C. Oppløsningen oppvarmes til 250°C og omrøres ved denne temperatur. Den dannede ethanol fordampes kontinuerlig fra reaksjonsblandingen. Den beregnede mengde alkohol kan avdampes i 30 - 40 minutter. Opparbeidelse: den avkjølte reaksjonsblanding fortynnes med 10 ml petrolether og ekstraheres med 3 x 100 ml 20%-ig saltsyre. Efter nøytralisasjon og ekstraksjon med benzen av saltsyrefasen fåes A) 14.6 g (0.05 mol) of 2-[(5-methyl-2-pyridyl)-amino-methylene]-succinic acid diethyl ester is dissolved in 100 ml diphyllo oil at 130°C. The solution is heated to 250°C and stirred at this temperature. The ethanol formed is continuously evaporated from the reaction mixture. The calculated amount of alcohol can evaporate in 30 - 40 minutes. Preparation: the cooled reaction mixture is diluted with 10 ml of petroleum ether and extracted with 3 x 100 ml of 20% hydrochloric acid. After neutralization and extraction with benzene, the hydrochloric acid phase is obtained
5% 3-(ethoxycarbonyl-methyl)-4-oxo-7-methyl-4H-pyrido-[1,2-a]-pyrimidin-fase. Utbytte: 50 - 55%. Smeltepunkt av basen efter omkrystallisasjon fra en dobbel mengde vannfri alkohol: 128 - 130°C. 5% 3-(ethoxycarbonyl-methyl)-4-oxo-7-methyl-4H-pyrido-[1,2-a]-pyrimidine phase. Yield: 50 - 55%. Melting point of the base after recrystallization from a double quantity of anhydrous alcohol: 128 - 130°C.
Ana lyse: Ana light:
Fra den 20%-ige saltsyrefase fremstilles l-(5-methyl-2-pyridyl)-3-ethoxycarbonyl-2-pyrrolin-5-on som beskrevet ovenfor. Produktet omkrystalliseres fra et like stort volum alkohol. Utbytte: 25 - 28%. Smeltepunkt: 96 - 98°C. From the 20% hydrochloric acid phase, 1-(5-methyl-2-pyridyl)-3-ethoxycarbonyl-2-pyrrolin-5-one is prepared as described above. The product is recrystallized from an equal volume of alcohol. Yield: 25 - 28%. Melting point: 96 - 98°C.
Analyse: Analysis:
B) Når 2-[(3-methyl-2-pyridyl)-amino-methylen]-ravsyre-diethylester anvendes som utgangsmateriale i ovenstående fremgangsmåte, fåes 3-(ethoxycarbonyl-methyl)-4-oxo-9-methyl-4H-pyrido-[l,2-a]-pyrimidin med smeltepunkt 88 - 90°C. C) Når 2-(2-kinolyl-amino-methylen)-ravsyre-diethylester anvendes som utgangsmateriale, fåes 3-(ethoxycarbonyl-methyl)-4-oxo-4H-pyrido-[1,2-a]-pyrimidin (smp. 121 - 122°C) i et utbytte på 60% (smp. 121 - 122°C) og 1-(2-kinolyl)-3-ethoxycarbonyl-2-pyrrolin-5-on i et utbytte på 7% (smp. 110 - 112°C). B) When 2-[(3-methyl-2-pyridyl)-amino-methylene]-succinic acid diethyl ester is used as starting material in the above process, 3-(ethoxycarbonyl-methyl)-4-oxo-9-methyl-4H- pyrido-[1,2-a]-pyrimidine with melting point 88 - 90°C. C) When 2-(2-quinolyl-amino-methylene)-succinic acid diethyl ester is used as starting material, 3-(ethoxycarbonyl-methyl)-4-oxo-4H-pyrido-[1,2-a]-pyrimidine is obtained (m.p. . 121 - 122°C) in a yield of 60% (m.p. 121 - 122°C) and 1-(2-quinolyl)-3-ethoxycarbonyl-2-pyrrolin-5-one in a yield of 7% (m.p. .110 - 112°C).
D) 10,8 9 (0,1 mol) 2-amino-6-methyl-pyridin og 20,2 g D) 10.8 9 (0.1 mol) 2-amino-6-methyl-pyridine and 20.2 g
(0,1 mol) 2-formyl-ravsyre oppløses i 150 ml difylolje. Oppløs-ningen omrøres og oppvarmes til 250°C i 1 time. Først destillerer vannet av og derefter ethanolen fra reaksjonsblandingen. Efter fordampning av den beregnede mengde vann og ethanol avkjøles opp-løsningen og behandles i henhold til fremgangsmåten beskrevet i eksempel A). Produktet renses ved kolonnekromatografi (Merck-kiselgel: partikkelstørrelse: 0,063 - 0,125 mm). Man får 3-(ethoxycarbony1-methy1)-4-oxo-6-methyl-4H-pyrido - [ 1,2-a]-pyrimidin i et utbytte på 25%. Smeltepunkt 89 - 90°C (eluert med benzen). (0.1 mol) 2-formyl-succinic acid is dissolved in 150 ml diphyllo oil. The solution is stirred and heated to 250°C for 1 hour. First the water distills off and then the ethanol from the reaction mixture. After evaporation of the calculated amount of water and ethanol, the solution is cooled and treated according to the method described in example A). The product is purified by column chromatography (Merck silica gel: particle size: 0.063 - 0.125 mm). 3-(ethoxycarbonyl-methyl)-4-oxo-6-methyl-4H-pyrido-[1,2-a]-pyrimidine is obtained in a yield of 25%. Melting point 89 - 90°C (eluted with benzene).
Analyse: Analysis:
Dessuten fåes 1-(6-methyl-2-pyridyl)-3-ethoxycarbonyl-3-pyrrolin-5-on i et utbytte på 15 - 20%. Smeltepunkt: 98 - 100°C. Analyse: In addition, 1-(6-methyl-2-pyridyl)-3-ethoxycarbonyl-3-pyrrolin-5-one is obtained in a yield of 15 - 20%. Melting point: 98 - 100°C. Analysis:
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUCI1361A HU168014B (en) | 1973-03-30 | 1973-03-30 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO741125A NO741125A (en) | 1974-10-01 |
NO140821B true NO140821B (en) | 1979-08-13 |
NO140821C NO140821C (en) | 1979-11-21 |
Family
ID=10994473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO741125A NO140821C (en) | 1973-03-30 | 1974-03-29 | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PYRIDO-PYRIMIDINE DERIVATIVES |
Country Status (20)
Country | Link |
---|---|
JP (1) | JPS505396A (en) |
AT (1) | AT336624B (en) |
BE (1) | BE813021A (en) |
CA (1) | CA1032938A (en) |
CH (1) | CH605940A5 (en) |
CS (1) | CS189872B1 (en) |
DD (1) | DD110661A1 (en) |
DE (1) | DE2414751A1 (en) |
DK (1) | DK138327B (en) |
ES (1) | ES424758A1 (en) |
FI (1) | FI57949C (en) |
FR (1) | FR2223036B1 (en) |
GB (1) | GB1454312A (en) |
HU (1) | HU168014B (en) |
IL (1) | IL44417A (en) |
NL (1) | NL7403901A (en) |
NO (1) | NO140821C (en) |
PL (1) | PL93755B1 (en) |
SE (1) | SE418087B (en) |
SU (1) | SU566524A3 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU173438B (en) * | 1975-11-27 | 1979-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing new 4-oxo-1,6,7,8-tetrahydro-4h-pyrido-/1,2-a/pyrimidine derivatives with antiinflammatory and anticoagulant activity |
HU174693B (en) * | 1976-02-12 | 1980-03-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing condensed pyrimidine derivatives |
HU174901B (en) * | 1976-06-25 | 1980-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing new pyrido /1,2-a/pyrimidine derivatives |
HU178910B (en) * | 1977-08-19 | 1982-07-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 2,3-disubstituted-4-oxo-4h-pyrido/1,2-a/-pyrimidines |
HU178496B (en) * | 1977-12-29 | 1982-05-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 6,7,8,9-tetrahydro-4h-pyrido/1,2-a/pyrimidine derivatives with antiallergic activity |
HU179143B (en) * | 1977-12-29 | 1982-08-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 9-hydroxy-groops-containing 6,7-dihydro-pyrido-square bracket-1,2-a-square bracket closed-pyrimidin derivatives and esters thereof |
HU185925B (en) * | 1977-12-29 | 1985-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing compounds with nitrogen bridge head |
HU180701B (en) * | 1977-12-29 | 1983-04-29 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing pyrido-/1,2-a/pyrimidines containing a carboxylic or ester group on the pirimidimering |
AT376675B (en) * | 1979-05-08 | 1984-12-27 | Erba Farmitalia | METHOD FOR PRODUCING NEW SUBSTITUTED PYRIDO (1,2-A) PYRIMIDINES |
US4661592A (en) * | 1984-06-27 | 1987-04-28 | G. D. Searle & Co. | 4H-pyrimido[2,1-a]isoquinolin-4-one derivatives |
HU201551B (en) * | 1988-02-03 | 1990-11-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing 4-oxo-4h-pyrido(1,2-a)pyrimidine-3-carboxylic acid amide derivatives and pharmaceutical compositions comprising same |
JP5419894B2 (en) * | 2008-01-11 | 2014-02-19 | グレンマーク ファーマシューティカルズ, エセ.アー. | Condensed pyrimidine derivatives as TRPV3 modulators |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT299212B (en) * | 1966-11-02 | 1972-06-12 | Chinoin Gyogyszer Es Vegyeszet | Process for the preparation of new homopyrimidazole derivatives and their salts |
-
1973
- 1973-03-30 HU HUCI1361A patent/HU168014B/hu unknown
-
1974
- 1974-03-13 IL IL44417A patent/IL44417A/en unknown
- 1974-03-22 NL NL7403901A patent/NL7403901A/xx unknown
- 1974-03-26 SE SE7404074A patent/SE418087B/en unknown
- 1974-03-27 DE DE2414751A patent/DE2414751A1/en not_active Withdrawn
- 1974-03-27 CS CS742217A patent/CS189872B1/en unknown
- 1974-03-27 AT AT252674A patent/AT336624B/en not_active IP Right Cessation
- 1974-03-27 FI FI940/74A patent/FI57949C/en active
- 1974-03-28 FR FR7410831A patent/FR2223036B1/fr not_active Expired
- 1974-03-28 CA CA196,195A patent/CA1032938A/en not_active Expired
- 1974-03-29 CH CH446974A patent/CH605940A5/xx not_active IP Right Cessation
- 1974-03-29 DD DD177572A patent/DD110661A1/xx unknown
- 1974-03-29 NO NO741125A patent/NO140821C/en unknown
- 1974-03-29 SU SU7402014577A patent/SU566524A3/en active
- 1974-03-29 DK DK174074AA patent/DK138327B/en not_active Application Discontinuation
- 1974-03-29 PL PL1974169922A patent/PL93755B1/en unknown
- 1974-03-29 BE BE142608A patent/BE813021A/en unknown
- 1974-03-29 ES ES424758A patent/ES424758A1/en not_active Expired
- 1974-03-30 JP JP49036582A patent/JPS505396A/ja active Pending
- 1974-04-01 GB GB1290874A patent/GB1454312A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
CH605940A5 (en) | 1978-10-13 |
HU168014B (en) | 1976-02-28 |
FR2223036A1 (en) | 1974-10-25 |
CS189872B1 (en) | 1979-05-31 |
AT336624B (en) | 1977-05-10 |
SE418087B (en) | 1981-05-04 |
ES424758A1 (en) | 1976-06-16 |
IL44417A0 (en) | 1974-06-30 |
CA1032938A (en) | 1978-06-13 |
IL44417A (en) | 1978-01-31 |
ATA252674A (en) | 1976-09-15 |
FI57949C (en) | 1980-11-10 |
DD110661A1 (en) | 1975-01-05 |
NO741125A (en) | 1974-10-01 |
PL93755B1 (en) | 1977-06-30 |
DK138327C (en) | 1979-01-22 |
AU6670474A (en) | 1975-09-18 |
DK138327B (en) | 1978-08-14 |
NL7403901A (en) | 1974-10-02 |
GB1454312A (en) | 1976-11-03 |
DE2414751A1 (en) | 1974-10-10 |
BE813021A (en) | 1974-07-15 |
NO140821C (en) | 1979-11-21 |
FR2223036B1 (en) | 1977-05-06 |
JPS505396A (en) | 1975-01-21 |
FI57949B (en) | 1980-07-31 |
SU566524A3 (en) | 1977-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU969164A3 (en) | Process for producing derivatives of phthalimidine or their salts | |
NO140821B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE PYRIDO-PYRIMIDINE DERIVATIVES | |
DE2658544A1 (en) | CARBOSTYRIL DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
NO154554B (en) | PROCEDURE FOR THE MANUFACTURING OF MINERAL BUILDING FIBERS. | |
US3714149A (en) | Pyridobenzodiazepinones | |
DE2835004A1 (en) | PYRIDO SQUARE CLAMP ON 1.2-ANGLE BRACKET FOR PYRIMIDINE DERIVATIVES, THE PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS | |
NO782108L (en) | NEW HEXAHYDROPYRIMIDINES, PROCEDURES FOR THEIR PREPARATION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
CA1083149A (en) | Derivatives of 10,11-dihydrobenzo 4,5 cyclohepta l,2- b -pyrazolo 4,3-e pyridine-5 (1h)ones | |
NO121950B (en) | ||
US4209622A (en) | 3-(Ethoxycarbonyl-methyl)-6-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine | |
NO158739B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-PIPERAZINOPYRIMIDINE DERIVATIVES. | |
DE2225765A1 (en) | 3-square brackets on 2- (4-phenyl-lpiperazinyl) -ethyl square brackets on -indoline | |
NO128025B (en) | ||
DD219765A5 (en) | METHOD FOR THE PRODUCTION OF SUBSTITUTED HEXAHYDROPYRROLO (-1,2-A) -QUINOLIN, HEXAHYDRO-1H-PYRIDO (1,2-A) CHINOLIN, HEXAHYDROBENZO (E) INDEN AND OCTAHYDROPHENANTHRENE CNS MEDIUM | |
NO137236B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF A THERAPEUTIC ACTIVE PIPERAZINYL-PYRIMIDINE DERIVATIVE. | |
NO762792L (en) | ||
US4420476A (en) | Benzofuro[3,2-c]pyrazol-3-amine derivatives | |
US3198800A (en) | 2, 8-(para-f-4-oxo-butyl)-diazaspiro[4, 5]-decane-1, 3-diones | |
US3583997A (en) | Benzothiopyrano(2,3-c)pyridines | |
SU1189349A3 (en) | Method of producing 6-substituted hexahydroindazolisoquinolines | |
NO162156B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE TRICYCLIC TIADIAZINO DERIVATIVES | |
NO143534B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY EFFECTIVE DERIVATIVES OF OXATIINO (1,4) (2,3-C) PYRROL | |
US3475438A (en) | Piperidine derivatives of dibenzobicyclo(5.1.0)octane | |
US3418317A (en) | 1h-2,3-benzoxazine-4(3h)-one and its 3- and/or 6-substituted derivatives | |
DE1695682A1 (en) | New heterocyclic compounds and processes for their preparation |